Nurix Therapeutics, Inc. NRIX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s additional paid-in capital?
- Nurix Therapeutics, Inc. (NRIX) reported additional paid-in capital of $1.57B in Q4 2025.
- How has Nurix Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Nurix Therapeutics, Inc.'s additional paid-in capital increased by 23.2% year-over-year, from $1.28B to $1.57B.
- What is the long-term trend for Nurix Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s additional paid-in capital has grown at a 31.4% compound annual growth rate (CAGR), from $393.84M to $1.54B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.